Wikidata

(Q63837986)

English

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

clinical trial

In more languages
default for all languages
No label defined

No description defined

Statements

title
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312. (English)
0 references
medical condition
sclerosis
0 references
multiple sclerosis
0 references
sponsor
Novartis
0 references
country
Argentina
0 references
Australia
0 references
Austria
0 references
Belgium
0 references
Bulgaria
0 references
Canada
0 references
Estonia
0 references
France
0 references
Germany
0 references
Greece
0 references
Hungary
0 references
Ireland
0 references
Israel
0 references
Italy
0 references
Japan
0 references
Latvia
0 references
Lithuania
0 references
Netherlands
0 references
Poland
0 references
Portugal
0 references
Romania
0 references
Slovakia
0 references
Spain
0 references
Sweden
0 references
Switzerland
0 references
Turkey
0 references
United Kingdom
0 references
start time
20 December 2012
0 references
end time
29 April 2016
0 references
number of participants
1,652
0 references
research site
Novartis
0 references
minimum age
18 year
0 references
maximum age
60 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q63837986&oldid=2235222040"